Syngene International Limited (NSE:SYNGENE)
India · Delayed Price · Currency is INR | Market Cap | 279.96B |
| Revenue (ttm) | 37.27B |
| Net Income (ttm) | 5.07B |
| Shares Out | 398.10M |
| EPS (ttm) | 11.90 |
| PE Ratio | 59.10 |
| Forward PE | 61.76 |
| Dividend | 1.25 (0.18%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 915,261 |
| Average Volume | 1,483,680 |
| Open | 714.00 |
| Previous Close | 714.00 |
| Day's Range | 701.45 - 714.35 |
| 52-Week Range | 599.55 - 960.60 |
| Beta | 0.03 |
| RSI | 67.16 |
| Earnings Date | Jul 22, 2025 |
About Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, prot... [Read more]
Financial Performance
In 2024, Syngene International's revenue was 36.42 billion, an increase of 4.41% compared to the previous year's 34.89 billion. Earnings were 4.96 billion, a decrease of -2.71%.
Financial StatementsNews
Goldman Sachs maintains buy on Syngene, bullish on FY26 early-teens growth outlook, sees 15.5% upside on Q1 beat and rising CRO-led margin gains
Goldman Sachs has retained a Buy rating on Syngene International, setting a target price of ₹775, which implies a potential upside of 15.5% from the current market price of ₹670.75. The brokerage high...
Syngene Q1 profit up 59% to Rs 87 crore
Syngene International's profit after tax surged 59% to Rs 87 crore in Q1 2025, driven by revenue growth and a tax benefit. Revenue from operations increased by 11% to Rs 875 crore, with EBITDA rising ...
Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY
Syngene International Limited reported strong financial results for the quarter ended June 30, 2025 (Q1 FY26), led by higher revenue and improved margins. For the quarter, the company’s revenue from o...
Syngene International receives EIR from USFDA for Biocon Park facility, inspection concludes with VAI classification
Syngene International Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its GMP manufacturing facilities located at Biocon ...
Why are Syngene shares down 10% despite Q4 net profit jumping 2.8% YoY?
Shares of Syngene International Ltd. tumbled 10% to Rs 674.25 in early trade on April 24, making it one of the top losers on the NSE. The sell-off came despite the company reporting a 2.8% year-on-yea...
Syngene International shares hit lower circuit crashing to 10% today after Q4 results
Shares of Syngene International Ltd. dropped 10% to Rs 674.25 in early trade on April 24 after the company posted lower-than-expected Q4 FY25 financials and offered a conservative revenue growth outlo...
Syngene International shares down 2.50% after USFDA issues Form 483 with five observations
Shares of Syngene International Ltd. fell nearly 2% in early trade on February 24 following an update on the USFDA inspection at its Bengaluru facility. The pharmaceutical contract research and manufa...
Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential
Shares of Suven Pharmaceuticals Ltd soared 12% today after Macquarie Equity Research initiated an ‘Outperform’ rating on multiple contract research, development, and manufacturing (CRDMO) companies, i...
Macquarie initiates Outperform call on Syngene International, Suven Pharma, Divi’s Lab, Blue Jet Healthcare
Macquarie has initiated coverage on India’s contract research, development, and manufacturing organization (CRDMO) sector, highlighting secular growth trends and regulatory tailwinds that are set to d...
Syngene International appoints Peter Bains as the CEO Designate of the company
Syngene International Limited has officially announced leadership changes as Jonathan Hunt steps down from his role as MD & CEO as well as from the Board of Directors. This transition is effective imm...
Syngene International shares fall nearly 6% on weak FY25 guidance and demand recovery delay
Shares of Syngene International Ltd, a subsidiary of Biocon, fell 5.91% to ₹796.90 on Friday, January 24, 2025, following a disappointing FY25 guidance update and concerns over delayed demand recovery...
Syngene shares surge after 2% equity worth Rs 706 crore changes hands in block deal
Syngene International witnessed a significant trading volume today as 82.2 lakh shares, representing 2% of the company’s equity, were exchanged via a block deal valued at ₹706 crore. The shares were t...
Syngene International’s market cap decreases by Rs 760 crore as shares drop 2.19% today – Know More
Shares of Syngene International Limited fell by 2.19% today, closing at Rs 842.75, down from the previous close of Rs 861.60. The decline led to an estimated market capitalization loss of Rs 760 crore...